Drug – bio-affecting and body treating compositions – Effervescent or pressurized fluid containing – Organic pressurized fluid
Reexamination Certificate
2000-03-14
2002-07-16
Bawa, Raj (Department: 1619)
Drug, bio-affecting and body treating compositions
Effervescent or pressurized fluid containing
Organic pressurized fluid
C424S046000, C424S489000
Reexamination Certificate
active
06419899
ABSTRACT:
BACKGROUND OF THE INVENTION
The invention relates to new propellant gases which contain as a typical ingredient 1,1,1,2,3,3,3-heptafluoropropane (TG 227), the use of these propellant gases in pharmaceutical preparations suitable for producing aerosols, and these pharmaceutical preparations themselves.
Aerosols of powdered (micronised) drugs are used widely in therapy, e.g., in the treatment of obstructive diseases of the respiratory tract. If such aerosols are not produced by atomizing the pharmaceutical powder or by spraying solutions, suspensions of the drugs in liquefied propellant gases are used. The latter consist primarily of mixtures of TG 11 (trichlorofluoromethane), TG 12 (dichlorodifluoromethane) and TG 114 (1,2-dichloro-1,1,2,2-tetrafluoroethane), optionally with the addition of lower alkanes such as butane or pentane, or with the addition of DME (dimethylether). Mixtures of this kind are known for example from German Patent 1178975.
Owing to their harmful effect on the earth's atmosphere (destruction of the ozone layer, Greenhouse effect) the use of chlorofluorocarbons has become a problem, with the result that the search is on for other propellant gases or propellant gas mixtures which do not have the above-mentioned harmful effects or, at least, have them to a lesser degree.
However, this search has come up against major problems, since propellant gases for therapeutical use have to satisfy numerous criteria which cannot easily be reconciled, e.g., in terms of toxicity, stability, vapor pressure, density and solubility characteristics.
REFERENCES:
patent: 4174295 (1979-11-01), Bargigia et al.
patent: 4352789 (1982-10-01), Thiel
patent: 4814161 (1989-03-01), Jinks et al.
patent: 5118494 (1992-06-01), Schultz et al.
patent: 5182097 (1993-01-01), Byron et al.
patent: 5605674 (1997-02-01), Purewal et al.
patent: 6153173 (2000-11-01), Sapsford et al.
patent: 2075058 (1991-08-01), None
patent: 0 247 608 (1987-12-01), None
patent: 0 384 371 (1990-08-01), None
patent: 902590 (1961-08-01), None
patent: 55 131 096 (1980-12-01), None
patent: 86/04233 (1986-07-01), None
Deger et al., “Specialty fluoroaliphatic chemicals”; a paper presented by Chemspec USA 1989; a symposium highlighting innovation, manufacture and applications of specialty chemicals, held at Hyatt Regency Chicago Hotel, 10-11 Oct. 1989.
Hoechst Press Release #7252; “Hoechst: Development of Alternatives to Fully Halogenated CFC's Takes Priority”; 1989.
Fischer et al., “CFC Propellant Substitution: International Perspectives”; Pharm. Technol., Inc., 1989; 1(2), 16-18.
Lachman et al., The Theory of Practice of Industrial Pharmacy”; 1986, Philadelphia, Ch. 20 p. 590 and 603-604.
Daab Ottfried
Weil Hans-Hermann
Bawa Raj
Boehringer Ingelheim KG
Devlin Mary-Ellen M.
Raymond Robert P.
Stempel Alan R.
LandOfFree
Suspension aerosol formulations of pharmaceutical products does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Suspension aerosol formulations of pharmaceutical products, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Suspension aerosol formulations of pharmaceutical products will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2907820